Safety and Immunogenicity of an Adjuvanted Monovalent COVID-19 Vaccine in Kidney Transplant Recipients with Low SARS-CoV-2 Antibody
Jianbo Xue(Peking University People's Hospital), William A. Werbel(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Sanaz Daneshfar Hamrah(Johns Hopkins University), Christian P. Larsen(Emory University Hospital), Brittany Barnaba(Johns Hopkins University), Peter S. Heeger(Cedars-Sinai Medical Center), Mark A. Robien(National Institute of Allergy and Infectious Diseases), Jia Li(Chinese Academy of Sciences), Christine M. Durand(University of Maryland, Baltimore)
Cited by 0
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|708